Prometic Biosciences Inc.

Prometic Pharma Smt Limited

Liminal Biosciences Limited

Biochem Pharma Inc.

Liminal R&d Biosciences Inc.

Shaun Abbott

Boulos Zacharie

Lyne Gagnon

Brigitte Grouix

Pierre Laurin

Christopher L Penney

Jean-François Bienvenu

Lilianne Geerts

Jean-Francois Bienvenu

Jeremy Green

Giorgio Attardo

Marc Courchesne

Guy Falardeau

Valérie Perron

Rabindra Rej

Serge Lamothe

Denis Labrecque

Jean-Simon Duceppe

Martin Leduc

François Sarra-Bournet

Abdallah Ezzitouni

Nicole Wilb

Daniel Fortin

Alan D Cameron

Karine Houde

Nancie Moreau

Julien Martel

Elodie Landagaray

Alexandre Larivée

Elyse Bourque

Mylène De Léséleuc

Claudio Sturino

Jean-Benoǐt Giguère

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.

GPR84 antagonists and uses thereof

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F or OH; Ris Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F, OH or CHPh; Ris H, F or OH; Q is

Substituted aromatic compounds and related method for the treatment of fibrosis

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, whereinA is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4;Ris H, F or OH;Ris Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4;Ris H, F, OH or CHPh;Ris H, For OH;Q is

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F or OH; Ris Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, F, OH or CHPh; Ris H, F or OH; Q is 1) (CH)C(O)OH wherein m is 1 or 2, 2) CH(CH)C(O)OH, 3) C(CH)C(O)OH, 4) CH(F)&#x2014;C(O)OH, 5) CF&#x2014;C(O)OH, or 6) C(O)&#x2014;C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.

The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is Calkyl, Calkyl, Calkenyl, Calkenyl, C(O)&#x2014;(CH)&#x2014;CHor CH(OH)&#x2014;(CH)&#x2014;CHwherein n is 3 or 4; Ris H, OH or F; Ris H, OH, F or CH&#x2014;OH; Ris H, OH, F or CHPh; Ris H, OH or F; Q is 1) (CH)C(O)OH wherein m is 1 or 2, 2) CH(CH)C(O)OH, 3) C(CH)C(O)OH, 4) CH(F)&#x2014;C(O)OH, 5) CF&#x2014;C(O)OH, or 6) C(O)&#x2014;C(O)OH. 

Substituted aromatic compounds for the treatment pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R&#x2550;C(0); &#x2014;OC(O)&#x2014; or &#x2014;CH(OH)&#x2014;; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction. 

Phenylketone carboxylate compounds and pharmaceutical uses thereof

We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases. 

Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives

Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.

Triazine dimers for the treatment of autoimmune diseases

The present invention is directed towards novel compounds that are effective inhibitors of integrins, particularly &agr; &bgr; or &agr; integrins such as &agr; &bgr; and &agr; &bgr; . One embodiment of the present invention comprises a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. R1, R2, R3, and R4 are defined herein.

Quinolizinones as integrin inhibitors

Growing community of inventors

Pointe-Claire, Canada

Shaun Abbott